EuroPCR 2018

EuroPCR is one of the largest, international courses in cardiovascular medicine. REVA presented positive 2-year data from the FANTOM II trial of the Fantom bioresorbable scaffold in 240 patients. Highlights from the presentations:

  • Low 5.0% rate of Major Adverse Cardiac Events (“MACE”)
  • A single very late scaffold thrombosis event for a rate of 0.4%
  • Sustained vessel lumen patency without evidence of chronic scaffold recoil.

See below for links to the data presentations.

Stay up-to-date with the latest news and information about Fantom and Fantom Encore.

REVA’s Symposium

Wednesday, 23 May 2018
12:15 to 13:15
Room 252B
FANTOM: the new vision of BRS performance

Chairpersons: Ulf Landmesser, Gregg W. Stone
Panelists: Alexandre Abizaid, Niels Ramsing Holm, Gregor Leibundgut, Matthias Lutz

Agenda:

Tyrocore: a proprietary polymer uniquely designed for vascular scaffolds <view presentation>
Presented by Dr. Gregor Leibundgut

New 24-month data from the FANTOM II clinical trial and initial results from Fantom BRS expansion trials <view presentation>
Presented by Dr. Alexandre Abizaid

Insights from the FANTOM II serial OCT sub-study <view presentation>
Presented by Dr. Niels Ramsing Holm

Fantom BRS case reviews and introduction to the REVA Technique <view presentation>
Presented by Dr. Matthias Lutz